CGTX COGNITION THERAPEUTICS INC Insider Trading

CEO Ricciardi bought 9,175 shares of CGTX at $1.10 on 2026-04-16; company unprofitable, stock down 64.8% from 52-week high

CEO Lisa Ricciardi purchased 9,175 shares at $1.10, adding 0.5% to her 1.71M-share position in a company reporting a full-year net income of -$4,930,000.00 (unprofitable). The transaction occurs as CGTX trades at $1.12, down 64.8% from its 52-week high of $3.18, though up 4.7% over the past 30 days. Her prior same-ticker purchases show mixed outcomes: a January 2025 buy resulted in -41.1% 30-day and -42.1% 90-day returns, while a March 2024 purchase delivered +12.0% and +36.0% returns respectively. The current purchase coincides with cluster activity—2 other insiders also bought within the past 14 days—suggesting coordinated interest at depressed valuations. However, the CEO's cross-ticker buy track record shows modest execution: 2 prior open-market purchases with an average 30-day return of -14.5% and 90-day return of -3.0%, with a 50% win rate at the 90-day mark.

CMO buys 10,000 CGTX shares at $1.11; cluster activity as 2 other insiders bought in past 14 days

Chief Medical Officer Anthony Caggiano purchased 10,000 shares at $1.11 on 2026-04-16, bringing his holdings to 874,906 shares. This buy occurs within a cluster pattern: 2 other insiders also made purchases within the past 14 days, suggesting coordinated insider accumulation during a period of material stress for the company. Cognition Therapeutics reported a net loss of $-4,930,000.00 over its most recent full fiscal year, and the stock is currently trading at $1.12, down 64.8% from its 52-week high of $3.18. The timing of multiple insider purchases during an unprofitable period and after a sharp decline warrants examination of whether recent developments (clinical, strategic, or otherwise) have altered insider assessment of the opportunity, though the small transaction size and depressed valuation make independent interpretation difficult without additional context.

CFO Doyle bought 10,000 shares of CGTX at $1.13; cluster of 2 other insiders also bought within 14 days amid -$4.9M net income

Doyle John Brendan, Chief Financial Officer, purchased 10,000 shares at $1.13 on 2026-04-16 during a period when COGNITION THERAPEUTICS was unprofitable, posting net income of -$4.9M over its most recent full fiscal year. This buy coincides with a broader insider cluster: 2 other insiders also purchased shares within the past 14 days, suggesting coordinated accumulation at depressed valuations relative to the 52-week high of $3.18 (current price is -64.8% from that peak). The stock has recovered 4.7% over the past 30 days but remains down 20.0% over 90 days, indicating the company is navigating a challenging period. The pattern of multiple insiders initiating purchases simultaneously, combined with the company's negative earnings, warrants attention as it may indicate leadership belief in recovery or asset value below market pricing, though the extended losses and stock performance provide material context for investors evaluating the signal.

CEO Lisa Ricciardi bought 38,851 shares of CGTX at $0.77 on 2025-01-31, increasing stake to 893,685 shares as stock trades 76.0% below 52-week high.

Lisa Ricciardi, CEO & President of Cognition Therapeutics, purchased 38,851 shares at $0.77 on 2025-01-31, a discretionary open-market transaction totaling $30,000.74. The purchase represents a 4.5% increase to her holdings, elevating her stake to 893,685 shares. Notably, the current price stands at $0.63, below the transaction price, and the stock has declined 76.0% from its 52-week high of $2.62, reflecting significant deterioration in valuation since Ricciardi's January purchase. The company reported net income of $-9,937,000.00 over its most recent full fiscal year, indicating ongoing losses, which provides material context for evaluating this transaction. Her prior buy at CGTX on 2024-03-14 demonstrated favorable 90-day returns (+36.0%), but the company's unprofitable status and the sharp pullback from recent highs suggest the timing of this current purchase may not replicate that pattern.